Market Cap (In GBp)
5.22 Million
Revenue (In GBp)
200 Thousand
Net Income (In GBp)
-1.74 Million
Avg. Volume
235.91 Thousand
- Currency
- GBp
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 3.3-9.5
- PE
- -
- EPS
- -
- Beta Value
- -0.31
- ISIN
- GB00BMDQ2T15
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Trevor Ajanthan Reginald
- Employee Count
- -
- Website
- https://www.roquefortinvest.com
- Ipo Date
- 2021-03-22
- Details
- Roquefort Therapeutics plc operates as a biotechnology research company. The company engages in the research and development of drugs targeting Midkine, a circulating growth factor protein and pro-inflammatory mediator for the treatment of cancer. Roquefort Therapeutics plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
More Stocks
-
600111
-
RPPINFRAR.P.P. Infra Projects Limited
RPPINFRA
-
VIBEFVibe Growth Corporation
VIBEF
-
102460
-
CGD
-
6914PSS Co.,Ltd.
6914
-
MMK
-
NDVNQnDivision Inc.
NDVNQ